Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 13/20 | 0.71 |
| ▸ | HDAC1 | Q13547 | 10/20 | 0.71 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.55 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21628436 | 0.89 | HDAC6 (0.59) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL4658281 | 0.83 | HDAC1 (0.56) | HDAC6HDAC1HDAC8SMN1; SMN2 | |
| SCHEMBL4657316 | 0.83 | HDAC1 (0.56) | HDAC6HDAC1HDAC8SMN1; SMN2 | |
| SCHEMBL24931337 | 0.83 | HDAC1 (0.72) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL105171 | 0.83 | HDAC6 (0.59) | HDAC6HDAC1HDAC8HDAC2CA2 | |
| SCHEMBL21146978 | 0.82 | HDAC1 (0.65) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL15480536 | 0.81 | HDAC8 (0.68) | HDAC6HDAC1HDAC8HDAC3MEN1 | |
| SCHEMBL2412211 | 0.81 | HDAC6 (0.50) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL624339 | 0.81 | KDM4E (0.61) | HDAC6HDAC1HDAC8HDAC2HDAC3 | |
| SCHEMBL104474 | 0.81 | MLYCD (0.59) | HDAC6HDAC1HDAC8MEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11723362-B2 | Broad-spectrum synergistic antimicrobial compositions | -The United States of America, as represented by The Secretary of Agriculture (US) | 2023-08-15 | — | — | US | disclosed |
| EP-4030915-A1 | BROAD-SPECTRUM SYNERGISTIC ANTIMICROBIAL COMPOSITIONS | The United States of America as represented by the Secretary of Agriculture (US) | 2022-07-27 | — | — | EP | disclosed |
| US-20210084896-A1 | BROAD-SPECTRUM SYNERGISTIC ANTIMICROBIAL COMPOSITIONS | METHOD PRODUCTS, PBC, | 2021-03-25 | — | — | US | disclosed |
| WO-2021055720-A1 | BROAD-SPECTRUM SYNERGISTIC ANTIMICROBIAL COMPOSITIONS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF AGRICULTURE (US) | 2021-03-25 | — | — | WO | disclosed |
| US-20200276180-A1 | POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR | HANGZHOU INNOGATE PHARMA CO., LTD (CN) | 2020-09-03 | — | — | US | disclosed |
| EP-3686196-A1 | POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR | Hangzhou Innogate Pharma Co., Ltd. (CN) | 2020-07-29 | — | — | EP | disclosed |
| US-20200165257-A1 | INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND HISTONE DEACETYLASE FOR TREATMENT OF CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2020-05-28 | — | — | US | disclosed |
| US-9969987-B2 | Split peroxidases and methods of use | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-05-15 | — | — | US | disclosed |
| US-9969987-B2 | Split peroxidases and methods of use | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2018-05-15 | — | — | US | disclosed |
| US-9714240-B2 | Vinyl autotaxin inhibitor compounds | PHARMAKEA, INC. (US) | 2017-07-25 | — | — | US | disclosed |
| US-20140206013-A1 | SPLIT PEROXIDASES AND METHODS OF USE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-07-24 | — | — | US | disclosed |
| US-20140186870-A1 | IN VIVO PROTEOMICS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2014-07-03 | — | — | US | disclosed |
| WO-2013059582-A2 | SMALL MOLECULE INHIBITORS OF HISTONE DEACTEYLASES | NUPOTENTIAL, INC. (US) | 2013-04-25 | — | — | WO | disclosed |
| WO-2012174479-A1 | IN VIVO PROTEOMICS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-12-20 | — | — | WO | disclosed |
| WO-2011106632-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2011-09-01 | — | — | WO | disclosed |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | AXYS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | US | disclosed |
| EP-1472216-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | Axys Pharmaceuticals (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2003066579-A2 | NOVEL BICYCLIC HYDROXAMATES AS INHIBITORS OF HISTONE DEACETYLASE | AXYS PHARMACEUTICALS (US) | 2003-08-14 | — | — | WO | disclosed |
| EP-0388389-A2 | Improved detergent compositions | MONSANTO EUROPE S.A./N.V. (BE) | 1990-09-19 | — | — | EP | disclosed |
| EP-0384912-A2 | Hydroxamate bleach stabilizer | MONSANTO COMPANY (US) | 1990-08-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165257-A1 | INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE AND HISTONE DEACETYLASE FOR TREATMENT OF CANCER | HDAC1, HDAC3, HDAC4 | HDAC6 10/4885HDAC1 1/4885HDAC8 6/4885 |
| US-11723362-B2 | Broad-spectrum synergistic antimicrobial compositions | HAO2, CAT, NACA | HDAC6 57/4885HDAC1 536/4885HDAC8 539/4885 |
| US-20200276180-A1 | POLYCYCLIC COMPOUND ACTING AS IDO INHIBITOR AND/OR IDO-HDAC DUAL INHIBITOR | IDO1, HDAC1, HDAC2 | HDAC6 9/4885HDAC1 2/4885HDAC8 15/4885 |
| US-20210084896-A1 | BROAD-SPECTRUM SYNERGISTIC ANTIMICROBIAL COMPOSITIONS | HAO2, CAT, NACA | HDAC6 57/4885HDAC1 536/4885HDAC8 539/4885 |
| US-20060058553-A1 | Novel bicyclic hydroxamates as inhibitors of histone deacetylase | HDAC1, HDAC2, HDAC11 | HDAC6 11/4885HDAC1 1/4885HDAC8 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.